Ranbaxy launches Atorvastatin

Cholesterol-reducing medication into the Canadian Healthcare System

Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that on Wednesday, May 19th, the Company gained approval from Health Canada to market RAN™-Atorvastatin Tablets (atorvastatin calcium), 10 mg, 20 mg, 40 mg, and 80 mg strengths, in the Canadian Healthcare System.  Atorvastatin is a cholesterol-reducing medicine, the generic equivalent of the brand Lipitor®, which has a current market size in Canada of $1.2 billion ($CAD) [IMS-CDH: February 2010]. 

“As a result of our global settlement, Ranbaxy is pleased to announce the immediate launch of RAN™-Atorvastatin.   Atorvastatin is a lipid metabolism regulator marketed under the Lipitor brand, representing the largest selling pharmaceutical brand in Canada,” said Paul Drake, President, RPCI.  RAN™-Atorvastatin will be made available to all Canadian patients under the Ranbaxy label, subject to Provincial formulary listings.

Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company.  RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

*Lipitor® is a registered trademark of Pfizer.